Annovis Bio, Inc. (ANVS)
| Market Cap | 71.03M +132.2% |
| Revenue (ttm) | n/a |
| Net Income | -40.92M |
| EPS | -1.77 |
| Shares Out | 34.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 769,651 |
| Open | 2.090 |
| Previous Close | 2.060 |
| Day's Range | 2.010 - 2.139 |
| 52-Week Range | 1.541 - 5.500 |
| Beta | 1.26 |
| Analysts | Buy |
| Price Target | 12.50 (+509.76%) |
| Earnings Date | May 15, 2026 |
About ANVS
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer’s disease, as well as in open-label phase 3 to treat parkinson’s disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer’s disease an... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for ANVS stock is "Buy." The 12-month stock price target is $12.5, which is an increase of 509.76% from the latest price.
News
Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results
Phase 3 AD trial: 85% of patients enrolled; full enrollment on track in summer 2026 PD open-label extension (OLE) study: 40% of patients enrolled; full enrollment on track in fourth quarter 2026 New D...
Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026
MALVERN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, ...
Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio
Buntanetap improved cognition in pTau217-positive early AD patients The drug reduced neurotoxic proteins as well as biomarkers of neuroinflammation and neurodegeneration Buntanetap was safe and well-t...
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission
MALVERN, Pa., April 10, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy...
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants
MALVERN, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy...
Annovis Bio secures U.S. patent for buntanetap
Annovis Bio (ANVS) announced the issuance of U.S. Patent No. 12,582,632 B2, covering prevention and treatment of neurological injuries arising from brain infections through the administration of bunta...
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
MALVERN, Pa., April 02, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy...
Annovis Publishes Historical Review of Buntanetap in The Scientist
MALVERN, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy...
Annovis Bio enters partnership with NeuroRPM
Annovis Bio (ANVS) announced a partnership with NeuroRPM to implement a new FDA-cleared artificial intelligence platform that collects movement data for symptom and disease management in its ongoing P...
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study
MALVERN, Pa., March 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy...
NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial
NeuroRPM's AI-enabled Apple Watch-based platform will provide continuous digital biomarker monitoring in Annovis Bio's Parkinson's disease clinical trial.
Annovis Bio sees cash runway to 3Q26
Annovis’ cash and cash equivalents totaled $19.5 million as of December 31, 2025 compared to $10.6 million as of December 31, 2024. The Company estimates that its current cash and…
Annovis Bio reports FY25 EPS ($1.40) vs. ($2.31) last year
“The year 2025 was a landmark period for Annovis, one in which we took decisive steps toward bringing buntanetap to patients,” said Maria Maccecchini, Ph.D., Founder and CEO of Annovis.
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results
MALVERN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy...
Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference
MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy...
Annovis Bio secures DSMB approval to advance Phase 3 trial of buntanetap
Annovis Bio (ANVS) announced that an independent Data and Safety Monitoring Board, DSMB, has issued a positive recommendation regarding the safety of buntanetap at 6 months, supporting the continuatio...
Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer's Disease
MALVERN, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy,...
Annovis Bio reports open-label extension study for Parkinson’s disease patients
Annovis Bio (ANVS) announced it will begin an open-label extension study in January 2026 to evaluate the long-term safety and efficacy of buntanetap in PD patients.
Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients
Enrollment will begin in January 2026 Participants will be treated with buntanetap for 36 months The study aims to enroll 500 patients MALVERN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc....
Annovis to Host Corporate Update Webinar on January 28, 2026
MALVERN, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurode...
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group
MALVERN, Pa., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurode...
Annovis Announces Two Presentations at the CTAD 2025 Conference
MALVERN, Pa., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurode...
Annovis announces FDA meeting to discuss PDD program
Annovis Bio (ANVS) announced that the U.S. Food and Drug Administration, FDA, has scheduled a Type C meeting in January 2026 to discuss the Company’s pathway for Parkinson’s disease dementia,…
Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study
MALVERN, Pa., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurode...
Annovis Bio announces biomarker data on amyloid co-pathology in Parkinson’s
Annovis Bio (ANVS) announced new data demonstrating the impact of amyloid co-pathology on cognitive outcomes in Parkinson’s patients and the therapeutic efficacy of buntanetap in this population. In t...